MDSpire - MDSpire Home

MDSpire - MDSpire Home

Region

United States US publications and network International Global sites and content

The premier global destination for healthcare professionals looking for trusted clinical content, breaking news, and a wealth of educational resources.

Conexiant.com
Conexiant Education

Trusted by leading healthcare organizations to deliver measurable engagement, education, and brand growth.

Conexiant Solutions
Conexiant DXP

MDSpire is an innovative platform aiming to create a smarter, faster, and more connected medical community.

MDSpire.com
DentalSpire.com

Association Partner

Our vision is a world free from digestive diseases. That's why it's our mission to empower clinicians and researchers to improve digestive health.

gastro.org
agau.org.gastro
myaga.gastro.org
foundation.gastro.org
agajournals.org
healthecareers.com

Conexiant.com
Conexiant Education

Conexiant DXP

MDSpire.com
DentalSpire.com

gastro.org
myaga.gastro.org
agajournals.org
agau.org.gastro
foundation.gastro.org

Advertisement

What is MDSpire?

MDSpire is an innovative platform aiming to create a smarter, faster, and more connected medical community.

Learn More

Choose specialties Cardiology Dermatology Endocrinology Family Medicine Gastroenterology Hematology Internal Medicine Neurology ObGyn Oncology Ophthalmology Optometry Pediatrics Rheumatology Pulmonary Psychiatry Pathology Surgery Orthopedic Medicine Radiology Otolaryngology Infectious Disease

The ASCO Post

April 3, 2026

Study Finds GLP-1RAs Were Associated With a Reduced Risk of Developing Colorectal Cancer vs Aspirin

Jo Cavallo
April 3, 2026
5 min

Colorectal cancer is the third most commonly diagnosed cancer in the U.S., with an estimated 154,270 new cases and 53,000 deaths in 2025, as reported by the Ame

...more

Colorectal cancer ranks third in diagnosis rates in the U.S.
154,270 new cases expected in
GLP-1RAs could reduce cancer risk by 36% compared to aspirin.
Aspirin has serious side effects limiting its use for prevention.
Study involved 281,656 participants matched on demographics.
Findings suggest GLP-1RAs may enhance public health strategies for cancer prevention.
Future research needed to validate these results.

The ASCO Post

April 3, 2026

FDA Grants Traditional Approval to Brexucabtagene Autoleucel for Relapsed or Refractory MCL

The ASCO Post Staff
April 3, 2026
4 min

The FDA has granted full approval to brexucabtagene autoleucel (Tecartus) for adult patients with relapsed or refractory mantle cell lymphoma (MCL) based on pos

...more

FDA has fully approved brexucabtagene autoleucel for MCL.
Approval based on ZUMA-2 study data.
High response rate (91%) in cohort 3, BTK inhibitor-naive patients.
MCL primarily affects older adults (>60 years).
Cytokine-release syndrome reported in 93% of patients.
Treatment demonstrates durable efficacy and manageable safety profile.
33,000 new MCL diagnoses annually worldwide.
Cohort size: 168 patients across all cohorts.

The ASCO Post

April 3, 2026

HER2CLIMB-05 Study: Tucatinib Enhances Progression-Free Survival as First-Line Maintenance for HER2-Positive Metastatic Breast Cancer

The ASCO Post Staff
April 3, 2026
10 min

The HER2CLIMB-05 study showcased that adding tucatinib to trastuzumab and pertuzumab significantly enhances progression-free survival in HER2-positive metastati

...more

Tucatinib significantly improves progression-free survival for HER2-positive MBC.
Study involved a randomized, double-blind phase III trial design.
Median progression-free survival: 24.9 months with tucatinib vs 16.3 months without.
Safety profile consistent with known toxicities.
54% of tucatinib patients remained on treatment at follow-up.
Benefits noted across all subgroups, including those with brain metastases.
High rates of manageable grade 3 adverse events.

April 3, 2026

Acoramidis Linked to Lower Mortality Through 54 Months

Andrea Surnit
April 3, 2026
3 min

Early and continuous therapy with acoramidis significantly reduced mortality and cardiovascular hospitalizations over 54 months in patients with transthyretin a

...more

Early acoramidis treatment improves survival in transthyretin amyloid cardiomyopathy.
Continuous therapy reduced all-cause mortality by 45%.
49% lower cardiovascular mortality was noted.
Functional capacity improved with continuous therapy.
Safety profiles showed no new long-term concerns.
Delayed initiation led to less favorable outcomes.
Study highlighted the need for timely treatment to enhance patient health.
Research funded by BridgeBio Pharma.

April 3, 2026

ADA Member Advantage-endorsed CyraCom joins Propio Language Services

Mary Beth Versaci
April 3, 2026
1 min

CyraCom, endorsed by ADA Member Advantage for nearly a decade, has been acquired by Propio Language Services, enhancing interpretation and translation services

...more

CyraCom has been endorsed by ADA for 9 years.
Propio Language Services acquired CyraCom.
ADA members retain familiar technology for services.
Services are available in hundreds of languages.
Competitive pricing benefits ADA members, including $0.59/min for Spanish.
No minimum use, setup fees, or contracts required.
Members pay only for minutes used monthly.
More information available at propio.com/ada.

The ASCO Post

April 3, 2026

AI Shows Dermatologist-Level Accuracy in Melanoma Diagnosis but Needs Validation

April 3, 2026
3 min

A recent systematic review and meta-analysis in JAMA Dermatology led by Sara Laiouar-Pedari evaluated the diagnostic performance of AI-assisted dermoscopy for m

...more

Systematic review and meta-analysis on AI in melanoma detection.
Included 11 prospective studies with over 2500 patients.
Dermatologists' sensitivity: 78.6%; AI sensitivity: 80.9%.
AI-assisted dermatologists showed improved results (sensitivity 91.9%).
Concerns about bias in study design impacting results.
Need for broader validation in unselected populations.

April 3, 2026

Molecular Testing Improves Nodular Fasciitis Diagnosis

Andrea Surnit
April 3, 2026
3 min

A study identified USP6 rearrangements in all clinically non-specific nodular fasciitis cases from 29 patients, where many presented with alarming histologic fe

...more

USP6 rearrangements identified in 100% of nodular fasciitis cases.
66% of cases initially had no suspicion for the condition.
Molecular testing crucial for accurate diagnosis.
Five atypical cases presented in unusual locations.
Younger patients had atypical gene fusions.
Study underscores importance of histopathology and molecular testing combined.

April 3, 2026

PRP Linked to Less Pain, Better Healing Following Tonsillectomy

Andrea Surnit
April 3, 2026
3 min

A randomized controlled trial led by Sedat Rüzgar at Bağcılar Training and Research Hospital evaluated the efficacy of topical autologous platelet-rich plasma (

...more

Study evaluated PRP effects in tonsillectomy.
Age range: 8-29 years.
Primary outcome: postoperative pain reduction.
Secondary outcomes included wound healing.
78% PRP group achieved full mucosal healing by day
Median pain scores improved by day
No major hemorrhages were reported.
Study had limitations such as single-center design.

April 3, 2026

Botulinum Toxin Evaluated in Digital Ischemia

Kathryn Wighton
April 3, 2026
3 min

A systematic review and individual participant data meta-analysis demonstrated that botulinum toxin injections significantly improve outcomes in patients suffer

...more

Botulinum toxin effectively treats digital ischemia, ulcers, and gangrene.
93% complete response for acute ischemia, 90% for ulcers.
Commonly used formulation: OnabotulinumtoxinA.
Minimal adverse events reported (e.g., 8% muscle weakness).
Predominantly female participants (75%), mean age
Underlying condition: systemic sclerosis (61%).
Treatment duration varied, fastest improvement in acute ischemia.

The Analytical Scientist

April 3, 2026

Spectroscopy’s Surprising LEGO Revolution

James Strachan
April 3, 2026
10 min

Richard Crocombe and colleagues have discovered that LEGO blocks serve as effective standard samples for overcoming fluorescence interference in Raman spectrosc

...more

LEGO blocks are effective standard samples for Raman spectroscopy.
Fluorescence interference is a key challenge for Raman instruments.
The choice of excitation wavelength notably affects spectral quality.
SPAD technology offers low-light detection but has current limitations.
No single method effectively handles fluorescence across all materials.
Further exploration into deep-UV excitation is planned for more insights.

The Pathologist

April 3, 2026

Slide Analysis, Rebuilt for Data Age

April 3, 2026
3 min

LazySlide is an innovative open-source software tool designed to enhance digital pathology analysis by integrating whole-slide images with laboratory data, as h

...more

LazySlide integrates digital pathology with molecular data.
Built in the scverse ecosystem for streamlined workflows.
Supports tissue segmentation, cell detection, and more.
Can link imaging data with RNA sequencing results.
New tools for searching and classifying tissue types.
Requires fewer steps for standard workflows.
Needs further clinical validation for effective use.
Aims to improve disease diagnosis through enhanced data integration.

The Pathologist

April 3, 2026

Scanning New Horizons (in Digital Pathology)

April 3, 2026
5 min

Andrew Mullen, the Digital Pathology Laboratory Supervisor at Nationwide Children’s Hospital, oversees innovative clinical and research programs in pediatric pa

...more

Digital Pathology Laboratory is crucial for pediatric pathology at Nationwide Children's Hospital.
Transitioned to primary diagnosis scanning in
Uses a hybrid model for faster and more efficient diagnostics.
Overcomes staffing and resource challenges through cross-training.
Supports global research initiatives through high-quality datasets.
Enhances collaboration among pathologists.
Digital tools are essential for recruiting specialized talent remotely.
Emphasizes the importance of technology in pediatric patient care.

April 3, 2026

Tinnitus Severity Linked to Depression, Anxiety

Andrea Surnit
April 3, 2026
2 min

A study conducted at a tertiary otolaryngology clinic involving 100 adults with chronic subjective tinnitus revealed a substantial link between tinnitus severit

...more

Study involved 100 adults with chronic tinnitus.
Severe tinnitus tied to higher depression & anxiety.
28% had moderate-to-severe depression.
Tinnitus severity accounted for 25% variation in depression.
Participants: Mean age 49; 58% female; 70% had hearing loss.
Used Tinnitus Handicap Inventory, Beck Depression, and Anxiety Inventories.
Limited by cross-sectional design and self-report measures.
Findings suggest mental health impacts from tinnitus severity.

April 3, 2026

TENS Added to Physical Therapy Lowers Fibromyalgia Pain

Andrea Surnit
April 3, 2026
5 min

Transcutaneous electrical nerve stimulation (TENS) effectively reduced movement-evoked pain in fibromyalgia patients when combined with physical therapy, accord

...more

TENS reduces movement-evoked pain in fibromyalgia patients.
Study included 459 patients from 28 clinics.
Patients using TENS reported greater pain reduction (mean difference: 1.2 points).
Improvements sustained for 6 months.
Modest effectiveness noted, especially with non-tailored therapy.
Minor adverse events were reported in about 30% of TENS users.
No serious adverse events linked to TENS.
TENS is a safe, nonpharmacologic therapy option for fibromyalgia.

April 3, 2026

Was the GLP-1 Problem Always Cost?

Kerri Miller
April 3, 2026
2 min

In a recent JAMA Viewpoint, Cleveland Clinic researchers Hamlet Gasoyan, DS, and Michael B. Rothberg, MD, analyze the implications of the CMS BALANCE model for

...more

Sixteen states initially covered GLP-1 medications; four have dropped coverage.
BALANCE model intends to standardize pricing/coverage for obesity-related medications.
Emphasizes obesity as a disease needing urgent acknowledgment.
Financial barriers significantly affect treatment adherence.
Advocacy for participation of state Medicaid and Medicare Part D is essential for success.
Implementation starts in July 2026 with a $50 co-pay for beneficiaries.

April 3, 2026

Retrorectal Surgery Linked to Low Recurrence

Andrea Surnit
April 3, 2026
3 min

A 25-year retrospective cohort study investigating surgical resection of retrorectal tumors revealed an impressive 5-year recurrence-free survival rate of 98% a

...more

Retrorectal tumors were studied over 25 years.
5-year recurrence-free survival rate was 98%.
Most tumors (95%) were benign, primarily tailgut cysts.
Preoperative biopsy indicated selective use due to complication risks.
Majority of patients underwent posterior resection.

The Ophthalmologist

April 3, 2026

Haag-Streit Announces Global launch of METIS 3D Digital Heads-Up Module

April 3, 2026
2 min

Haag-Streit has launched the METIS 3D Digital Heads-Up Module (METIS HU), enhancing their METIS 900 ophthalmic microscope with a state-of-the-art integrated dig

...more

METIS 3D Digital Heads-Up Module launched by Haag-Streit.
Features an integrated digital 3D visualization platform.
Incorporates advanced 3D 4K camera technology.
Reduces neck and back strain for surgeons.
Enhances surgical visualization for delicate procedures.
Debuted at the AAO Meeting in October
Will be showcased at multiple international congresses.
Offers a modern, connectivity-focused platform.

The Ophthalmologist

April 3, 2026

SEE Program Strengthens Adherence

April 3, 2026
3 min

A randomized clinical trial published in JAMA Ophthalmology showed that a motivational interviewing-based coaching program, called Support, Educate, Empower (SE

...more

SEE trial aimed to improve glaucoma medication adherence.
Enrolled 235 adults with self-reported poor adherence.
Intervention included in-person sessions and automated reminders.
Adherence improved from 63.9% to 77.6%.
Over half of SEE participants achieved ≥80% adherence.
Reduced glaucoma-related distress significantly.
Suggests personalized strategies are more effective than traditional methods.

Advertisement

Advertisement

Advertisement

About
Privacy Policy

Follow Us